Zeltia

Last updated

Zeltia, S.A.
Type Sociedad Anónima
BMAD:  ZEL
ISIN ES0184940817
Industry Pharmaceutical
Founded Vigo, Galicia, Spain (August 3, 1939 (1939-08-03))
Defunct2015 (2015)
Headquarters
Madrid
,
Spain
Area served
Worldwide
Key people
José Fernández Sousa-Faro (Chairman)
ProductsPharmaceuticals
RevenueIncrease2.svg US$176 million (2009)
Increase2.svg (US$46.3) million (2009)
Increase2.svg (US$40.3) million (2009)
Total assets Increase2.svg US$302.9 million (2009)
Total equity Decrease2.svg US$59 million (2009)
Subsidiaries PharmaMar, Genómica, Sylentis, Zelnova, Xylazel
Website www.zeltia.com
Footnotes /references
[finan 1] [history 1]

Zeltia is a former Spanish pharmaceutical company which operated through a variety of subsidiaries in the pharmaceutical and chemical industries. As of 2007, Zeltia's research activities in the pharmaceutical area had not resulted in a marketed product. [history 2] However, the company's majority shareholder and chairman are the same person, which has relieved the pressure which many CEOs have experienced to produce immediate returns. [history 3]

Contents

History

In 1993 Zeltia sells its subsidiary Cooper-Zeltia taking the name CZ Veterinaria, which years later would be renamed Zendal. [1]

The company was taken over by its subsidiary Pharma Mar in a reverse takeover, keeping the Zeltia's Group structure.

Subsidiaries

Direct subsidiaries as of 2009 were: [finan 2] Pharma Mar, S.A.U.; Genómica, S.A.U.; Zelnova, S.A; Protección de Maderas, S.A.U; Xylazel, S.A.; Noscira, S.A.; Sylentis, S.A.

Indirect subsidiaries which are direct subsidiaries of Pharma Mar as of 2009 were: [finan 2] Pharma Mar US; Pharma Mar AG; PharmaMar S.A.R.L.; Pharma Mar GmbH; Pharma Mar Ltd.

A single indirect subsidiary is a direct subsidiary of Zelnova, that being Copyr, S.p.A. [finan 2]

Related Research Articles

Pfizer American multinational pharmaceutical corporation

Pfizer Inc. is an American multinational pharmaceutical and biotechnology corporation headquartered on 42nd Street in Manhattan, New York City. The company was established in 1849 in New York by two German immigrants, Charles Pfizer (1824-1906) and his cousin Charles F. Erhart (1821-1891).

An epinephrine autoinjector is a medical device for injecting a measured dose or doses of epinephrine (adrenaline) by means of autoinjector technology. It is most often used for the treatment of anaphylaxis. The first epinephrine autoinjector was brought to market in 1983.

Generic drug Pharmaceutical equivalent to a brand-name product

A generic drug is a pharmaceutical drug that contains the same chemical substance as a drug that was originally protected by chemical patents. Generic drugs are allowed for sale after the patents on the original drugs expire. Because the active chemical substance is the same, the medical profile of generics is believed to be equivalent in performance. A generic drug has the same active pharmaceutical ingredient (API) as the original, but it may differ in some characteristics such as the manufacturing process, formulation, excipients, color, taste, and packaging.

Many countries have measures in place to limit advertising by pharmaceutical companies.

Bausch Health Companies Inc. is a multinational specialty pharmaceutical company based in Laval, Quebec, Canada. It develops, manufactures and markets pharmaceutical products and branded generic drugs, primarily for skin diseases, gastrointestinal disorders, eye health and neurology. Bausch Health owns Bausch & Lomb, a supplier of eye health products.

Baxter International Inc. is an American multinational health care company with headquarters in Deerfield, Illinois.

Sanofi Pasteur is the vaccines division of the French multinational pharmaceutical company Sanofi. Sanofi Pasteur is the largest company in the world devoted entirely to vaccines.

Teva Pharmaceuticals Israeli pharmaceutical company

Teva Pharmaceutical Industries Ltd., also known as Teva Pharmaceuticals, is an Israeli-American multinational pharmaceutical company with headquarters in Petah Tikva, Israel and Parsippany, New Jersey, United States. It specializes primarily in generic drugs, but other business interests include active pharmaceutical ingredients and, to a lesser extent, proprietary pharmaceuticals. In 2020, Teva Pharmaceuticals was the second largest generic drug manufacturer and the eighteenth largest pharmaceutical company in the world.

Daiichi Sankyo Japanese pharmaceutical company

Daiichi Sankyo Company, Limited is a global pharmaceutical company and the second-largest pharmaceutical company in Japan. It achieved JPY 981.8 billion in revenue in 2019. The company owns the American biotechnology company Plexxikon, American pharmaceutical company American Regent, German biotechnology company U3 Pharma, and recently sold Ranbaxy Laboratories in India. Daiichi Sankyo Co., Ltd. is the producer of Benicar (Olmesartan), an angiotensin II receptor antagonist and top selling drug in the U.S. Global sales of Olmesartan in 2013 were 300.2 billion yen.

OSI Pharmaceuticals, Inc. was an American pharmaceutical company formerly based on Long Island, New York with facilities in Colorado, New Jersey and the United Kingdom. On Sunday, May 16, 2010 OSI agreed to be acquired by Japan-based, TSE-listed Astellas Pharma for $4.0 billion. The deal was closed on June 9, 2010. The company closed its last facilities on Long Island in May 2013. OSI had specialized in the discovery and development of molecular targeted therapies. Though oncology was the top priority for OSI, research and development targeting type 2 diabetes and obesity was conducted through their U.K. subsidiary Prosidion Limited. OSI has also made a foray into the ophthalmology market through a marketing agreement with Pfizer over Macugen (Pegaptanib) for Age-related macular degeneration; however, acquisition of the firm Eyetech, meant to provide control over this product and diversify the company, was unsuccessful, ending in divestiture.

Basilea Pharmaceutica

Basilea Pharmaceutica is a multinational specialty biopharmaceutical company headquartered in Basel, Switzerland. It was formed as a spin-off entity from the drug giant Hoffmann–La Roche in October 2000. It is engaged in the development of antibiotics, antifungals and oncology drugs for treatment of invasive aspergillosis and invasive mucormycosis. Basilea is publicly traded on the SIX Swiss exchange.

Grifols, S.A. is a Spanish multinational pharmaceutical and chemical manufacturer. Principally a producer of blood plasma-based products, a field in which it is the European leader and largest worldwide, the company also supplies devices, instruments, and reagents for clinical testing laboratories.

Sun Pharma Indian multinational pharmaceutical company

Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra, that manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) primarily in India and the United States. Sun Pharma has presence in more than 100 countries across the globe. It is largest pharma company in India and the fourth largest specialty generic pharmaceutical company in the world, with a total revenue of over US$4.5 billion as of June 2021. The products cater to a vast range of therapeutic segments covering psychiatry, anti-infectives, neurology, cardiology, orthopaedic, diabetology, gastroenterology, ophthalmology, nephrology, urology, dermatology, gynaecology, respiratory, oncology, dental and nutritionals. Its API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol.

CSPC Pharmaceutical Group researches, develops, manufactures and sells pharmaceutical products. Its headquarters is in China's Hebei Province.

Sumitomo Dainippon Pharma

Sumitomo Dainippon Pharma Co., Ltd. is a pharmaceutical company based in Japan. Its headquarters are in Chuo-ku, Osaka.

Lupin Limited Indian multinational pharmaceutical company

Lupin Limited is an Indian multinational pharmaceutical company based in Mumbai, Maharashtra, India. It is one of the largest generic pharmaceutical companies by revenue globally. The company's key focus areas include paediatrics, cardiovascular, anti-infectives, diabetology, asthma and anti-tuberculosis.

Ajanta Pharma Limited (APL) is a multinational company based in India engaged in development, manufacturing, and marketing of pharmaceutical formulations. It has a presence in India, the United States, and about 30 other countries in Africa, Asia, Middle East, and CIS. It was established in 1973.

GW Pharmaceuticals

GW Pharmaceuticals is a British pharmaceutics company known for its multiple sclerosis treatment product nabiximols which was the first natural cannabis plant derivative to gain market approval in any country. Another cannabis-based product, Epidiolex, was approved for treatment of epilepsy by the US Food and Drug Administration in 2018. It is a subsidiary of Jazz Pharmaceuticals.

Alvogen is an American pharmaceuticals company founded in 2009. In 2014 a controlling stake in the company was acquired by CVC Capital Partners and Temasek Holdings. Alvogen has about 350 different medical and non-medical products, and both produces its own products and markets the products of brand name pharmaceutical companies.

PharmaMar Spanish pharmaceutical company

PharmaMar is a Spanish pharmaceutical company headquartered in Colmenar Viejo, Madrid, Spain. Founded in 1986 as a subsidiary of Zeltia, it absorbed its parent company and all its subsidiaries in a reverse merger takeover in 2015. The company is a component of the Madrid Stock Exchange General Index (IGBM) and the IBEX 35 since 2020, after being part of the Ibex Small Cap stock market index.

References

  1. "El pueblo que levantó una industria". La Voz de Galicia. August 31, 2015.

Financial

  1. "Zeltia, S.A." (database record). Austin, Texas, United States: Hoover's. Companies. Retrieved May 7, 2011.
  2. 1 2 3 "Consolidated Financial Statements as of 31 December 2009". Zeltia. April 16, 2010. Retrieved May 7, 2011.

History

  1. Bueno, María José Sánchez (2008), El proceso innovador y tecnológico: estrategias y apoyo público (Google Books) (in Spanish), Netbiblo, p. 175, ISBN   978-84-9745-240-3, OCLC   434255490 , retrieved May 7, 2011
  2. Clark, Todd D. (2007), "Spain", PharmaHandbook: a guide to the international pharmaceutical industry (Google Books) (5 ed.), New Orleans, Louisiana, United States: Value of Insight Consulting, p. 381, ISBN   978-0-9795443-0-9, OCLC   254331162 , retrieved May 7, 2011
  3. Jericó, Pilar (2009), "The Price of Fear", No Fear: In Business and In Life (Google Books), Basingstoke, United Kingdom: Palgrave Macmillan, p. 66, ISBN   978-0-230-58038-1, OCLC   636422030 , retrieved May 7, 2011